Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...
The round was led by F-Prime Capital, with participation from Bienville Capital Management and Thayer Ventures. The investment will further TripSuite's mission to enhance the agency and traveler ...
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Metastatic Ovarian Cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback